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Abstract 
Quantification of Ȗ-aminobutyric acid (GABA) concentration using localized MRS suffers from 
partial volume effects related to differences in the intrinsic concentration of GABA in grey 
matter (GM) and white matter (WM). These differences can be represented as a ratio between 
intrinsic GABA in GM and WM, rM. Individual differences in GM tissue volume can therefore 
potentially drive apparent concentration differences. Here, a quantification method that corrects 
for these effects is formulated and empirically validated. Quantification using tissue water as an 
internal concentration reference has previously been described. Partial volume effects attributed 
to rM can be accounted for by incorporating into this established method an additional 
multiplicative correction factor based on measured or literature values of rM weighted by the 
proportion of GM and WM within tissue-segmented MRS volumes. Simulations were performed 
to test the sensitivity of this correction using different assumptions of rM taken from previous 
studies. The tissue correction method was then validated by applying it to an independent dataset 
of in vivo GABA measurements using an empirically measured value of rM. It is shown that 
incorrect assumptions of rM can lead to overcorrection and inflation of GABA concentration 
measurements quantified in volumes composed predominantly of WM. For the independent 
dataset, GABA concentration was linearly related to GM tissue volume when only the water 
signal was corrected for partial volume effects. Performing a full correction that additionally 
accounts for partial volume effects ascribed to rM successfully removed this dependency. With 
appropriate assumption of the ratio of intrinsic GABA concentration in GM and WM, GABA 
measurements can be corrected for partial volume effects, potentially leading to a reduction in 
between-participant variance, increased power in statistical tests and better discriminability of 
true effects. 
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Introduction 
An outstanding problem in the quantification of Ȗ-aminobutyric acid (GABA) 
concentration is the issue of partial volume effects, which arise from signal detection in MRS 
volumes composed heterogeneously of grey matter (GM), white matter (WM) and cerebrospinal 
fluid (CSF). Partial volume effects will lead to differences in apparent GABA concentration 
(e.g., between two participant groups) that are dependent on differences in voxel tissue content 
but not necessarily on differences in intrinsic concentrations of GABA. Additionally, accounting 
for tissue differences may reduce the variability of concentration measurements (1), thereby 
increasing both the power in statistical analyses and the likelihood of detecting true differences. 
Partial volume effects also have implications for the signal-to-noise ratio of detected spectral 
peaks, where variations in tissue content will lead to differences in signal intensity. 
Early post-mortem studies have indicated that GABA content is nonuniform across the 
mammalian cerebrum. Fahn and Côté (2) reported large variability in concentration in rhesus 
monkeys, with highest GABA levels found in subcortical regions (e.g., basal ganglia) and lowest 
in pure WM (centrum semiovale). Petroff et al. (3) measured GABA concentration in biopsied 
rabbit brains, revealing two times greater levels in GM compared to WM. Comparatively higher 
GABA in GM has also been seen in the monkey brain (4). The use of 1H MRS has also revealed 
regional differences of in vivo GABA across the brain in rats (5) and humans (6–10). 
A number of studies have reported a positive linear dependence of MRS-measured 
GABA on GM volume, where the amount of GABA in pure GM and pure WM can be estimated 
by linear regression given sufficient variability in tissue content (11). GABA detection using 
chemical shift imaging (CSI) has been particularly useful in characterizing this relationship given 
the large range in fractional GM volume sampled across the acquisition slab. CSI studies have 
shown two- to eight-fold increases in GABA in GM compared to WM (12–14). Single voxel 
spectroscopy (SVS) experiments have also shown similar findings within more regionally 
specific volumes (15–18). 
This dependency on GM volume has implications for studies that include systematic 
differences in fractional GM voxel volume either between experimental groups or across 
individual participants. For instance, in a hypothetical case one set of GABA measurements has 
been quantified in predominantly WM voxels (such as where significant atrophy in GM has 
occurred) and is compared to another dataset from a healthy cohort with no GM atrophy. A 
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difference will likely be apparent but this may not be due to intrinsic differences in GABA 
concentration but rather to differences in tissue content between the two cohorts. Confounds will 
also occur where GABA is correlated with a behavioral measure (e.g., impulsivity) or a 
functional imaging signal (e.g., the blood oxygenation level dependent response) when these 
other variables also show a dependency on GM volume. Positive relationships between GABA, 
GM and some other variable of interest will lead to overestimation of the association between 
GABA and the variable of interest. In contrast, a negative relationship between GM and a 
variable of interest will lead to underestimation of the positive association between GABA and 
this variable. Accounting for heterogeneous tissue content therefore constitutes an important step 
for accurate quantification of in vivo GABA in MRS studies. 
 However, a hindrance to the implementation of such an approach is the appropriate 
assumption of the ratio of intrinsic GABA concentration in GM and WM (rM). Harris et al. (19) 
recently introduced a comprehensive tissue correction method that accounts for intrinsic GABA 
signal differences due to partial volume effects. Crucially, their method relies on assuming the 
ratio of GABA in GM and WM (i.e., rM). The effect of various ratios on simulated data was 
investigated, where an rM value of 2 was predicted to be the most appropriate. This value was 
then used to correct in vivo data for voxel tissue content differences across participants, where it 
did not lead to significantly increased variance in the dataset of tissue-corrected GABA 
concentration measurements. 
Here, a tissue correction method mathematically similar to Harris et al. (19) is 
formulated. However, a different approach is taken in that the ratio of GABA in GM and WM 
specific to a given region is empirically estimated in a large reference dataset. In many cases a 
reference dataset may not be available to research groups and rM would have to be assumed from 
the literature. We additionally seek to show how various assumptions of rM taken from previous 
studies influence the correction. Therefore, our aims were threefold: Firstly, to estimate rM in the 
occipital lobe of a large reference cohort. Secondly, to simulate the impact of assuming rM from 
literature values when correcting GABA concentration measurements quantified in tissue-
heterogeneous volumes. Thirdly, to validate this tissue correction method by applying it to 
occipital GABA measurements quantified in an independent cohort. These were derived from 
both macromolecule (MM) -contaminated and -suppressed acquisitions, such that the tissue 
correction method could be validated for both types of GABA measurements.  
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Theory 
The NMR signal of a given metabolite is proportional to its molar or molal concentration 
scaled by constants related to the scanner system and the biochemical sample: 
 ܵெ = �ܴெ�ெ [1] 
where SM is the observed signal of the metabolite of interest, k is a complex global 
proportionality constant containing numerous system scaling factors (e.g., receive gain, coil 
loading, pulse sequence design, voxel volume, etc.) and CM is the metabolite concentration 
(equal to the number of moles of the molecule). The signal attenuation factor RM accounts for the 
transverse and longitudinal relaxation of the metabolite: 
 ܴெ = exp (− ்ா்మ,ಾ) [1 − exp (− ்ோ்భ,ಾ)] [2] 
where TE and TR are the echo and repetition times of the acquisition and T1,M and T2,M are the T1 
and T2 relaxation times of the metabolite. It is assumed that the relaxation times of metabolites 
do not differ markedly across GM and WM (20–23). 
For a given localized spectroscopic voxel, the metabolite concentration will be equal to a 
weighted sum of the intrinsic concentration of the metabolite in each MR-visible tissue 
compartment in the brain (11,24). This can be formulated as follows: 
 �ெ = ߙݔ + ߚݕ + ߛݖ [3] 
where α, ȕ and Ȗ are the volume fractions of GM, WM and CSF within the voxel and x, y and z 
represent the basis concentrations of the metabolite in GM, WM and CSF. It is important to note 
that Eq. [3] assumes that the basis metabolite concentration for each compartment does not 
change throughout the cerebrum. 
GM, WM and CSF volumes in the voxel can be determined by tissue segmentation 
algorithms available in widely used MRI software packages (e.g., FSL, SPM or FreeSurfer), such 
that the terms α, ȕ and Ȗ equate to the fractional voxel volumes for each tissue compartment: α = 
fGM, ȕ = fWM, Ȗ = fCSF. The basis concentrations can now be represented as: x = MGM, y = MWM, z 
= MCSF. Rewriting Eq. [1] gives 
 ܵெ = �ܴெሺ�ீ ெ�ீெ + ��ெ��ெ + � �ௌி��ௌிሻ [4] 
The concentration of most metabolites in CSF is negligible (25,26). Therefore, the CSF 
terms can be removed from the equation. This then requires that the GM and WM voxel volume 
terms be normalized by the amount of tissue in the voxel. Eq. [4] then becomes 
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 ܵெ = �ܴெ [�ಸಾெಸಾଵ−���ಷ ሺ1 − ��ௌிሻ + ��ಾெ�ಾଵ−���ಷ ሺ1 − ��ௌிሻ] [5] 
fGM and fWM are normalized by the volume of tissue in the voxel: 
 �ீெ = �ಸಾଵ−���ಷ [6] 
 ��ெ = ��ಾଵ−���ಷ [7] 
where tGM and tWM are the fractional GM and WM volumes per unit tissue volume. We now 
obtain 
 ܵெ = �ܴெ[�ீெ�ீெሺ1 − ��ௌிሻ + ��ெ��ெሺ1 − ��ௌிሻ] [8] 
 ܵெ = �ܴெሺ�ீெ�ீெ + ��ெ��ெሻሺ1 − ��ௌிሻ [9] 
Since the tissue volumes are based in terms of GM and WM, the basis concentrations of the 
metabolite can be interpreted as a ratio of MGM to MWM, as so: 
 �ெ = ெಸಾெ�ಾ [10] 
Eq. [9] can be rewritten giving 
 ܵெ = �ܴெሺ�ீெ�ெ��ெ + ��ெ��ெሻሺ1 − ��ௌிሻ [11] 
The basis concentrations are now relative to the concentration of the metabolite in pure WM. 
Consequently, when rM = 1, MGM = MWM. 
It is common practice in metabolite quantification to standardize to an internal reference 
(27,28), the signal of which will also be dependent on the tissue composition of the voxel. In 
such a case, Eq. [11] is modified to become 
 
ௌಾௌಿ = ோಾሺ�ಸಾ�ಾெ�ಾ+��ಾெ�ಾሻோಿሺ�ಸಾ�ಿே�ಾ+��ಾே�ಾሻ ሺ1 − ��ௌிሻ [12] 
where k is cancelled out (since the reference signal is detected in the same way as the metabolite 
of interest) and the N terms refer to the reference, which are treated in the same manner as the M 
terms. 
While the choice of a reference is important for a multitude of reasons, such as for being 
certain any possible effect of a metabolite of interest is due to the metabolite itself and not the 
reference, correcting for heterogeneous tissue content adds another layer of complexity. From 
Eq. [12] it can be seen that assuming inappropriate basis concentrations for either the metabolite 
of interest or the reference will adversely affect the quantified metabolite concentration. It is 
useful to frame this potential pitfall by considering the normalization factor needed to correct for 
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partial volume effects. This is a multiplicative tissue correction factor derived from Eq. [11] and 
is formulated as follows: 
 �ܶ��� = ሺ�ீெ�ெ��ெ + ��ெ��ெሻ−ଵ [13] 
It is important to make clear that the purpose of this normalization is to scale measured 
concentrations to the concentration that would have been measured if the voxel in which the 
signal was detected were 50% GM and 50% WM. Therefore, the basis concentrations MGM and 
MWM must each be divided by the mean of MGM and MWM when performing this correction. In 
this way, Tcorr will equal 1 (i.e., no correction) if tGM = 0.5. Figure 1 displays Tcorr as a function of 
tGM based on a range of assumptions of rM. It can be clearly seen that incorrectly assuming a 
large rM value will lead to inflation of concentration values measured in voxels composed 
predominately of WM. Thus, inappropriate assumptions of the ratio of the intrinsic metabolite 
concentration in GM and WM could significantly bias measurements when there is large 
variability in fractional voxel volumes across participants or groups. 
For relative quantification (referencing to another metabolite), the basis concentrations 
for the reference typically would be taken from previous studies in the literature. When absolute1 
concentration values are desired, a common method is to use tissue water as an internal 
concentration reference. The use of tissue water as an internal standard has been described 
extensively (29–34). The major advantages of water referencing over metabolite referencing 
include the ability to compare data across sites, high signal-to-noise ratio of the water peak and 
relative ease of acquisition (28). The observed water signal is not homogenous throughout brain 
tissue, however; tissue-dependent signal relaxation and water density differences have to be 
taken into account. Gasparovic et al. (35) have described an absolute quantification method that 
accounts for the differential density and relaxation times of water in voxels composed of 
nonuniform proportions of GM, WM and CSF, formulated as follows: 
 �ெ =  ௌಾ(�ಸಾ�ಹమೀ,ಸಾோಹమೀ,ಸಾ+��ಾ�ಹమೀ,�ಾோಹమೀ,�ಾ+���ಷ�ಹమೀ,��ಷோಹమೀ,��ಷ)ௌಹమೀோಾሺଵ−���ಷሻ ቀ#ுಹమೀ#ுಾ ቁ �ுଶை [14] 
where SH2O is the observed water signal, ρH2O,y is the relative density of MR-visible water in 
compartment y, #HH2O and #HM are the number of protons that give rise to the water and 
                                                 
1
 The definition of the term “absolute” in metabolite quantification in MRS is controversial and often ambiguous. In 
this paper, absolute is used to mean that the signal ratio has been calibrated using an internal standard (some 
reference compound) with an assumed concentration. Other factors that modulate the signal ratio are also assumed. 
Concentrations are not expressed in conventional biochemical units (mM or µmol/g) but instead in institutional units 
(i.u.). 
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metabolite peaks and CH2O is the molar concentration of water (55,000 mM). The differential 
longitudinal and transverse relaxation times of water in each tissue compartment are corrected 
for by the attenuation factor RH2O,y (see Eq. [2]). In similar fashion, the metabolite of interest 
could be referenced to internal tissue water according to Eq. [12], where the signal ratio is 
 
ௌಾௌಹమೀ = ோಾሺ�ಸಾ�ಾெ�ಾ+��ಾெ�ಾሻሺଵ−���ಷሻோಹమೀሺ�ಸಾுଶைಸಾ+��ಾுଶை�ಾ+���ಷுଶை��ಷሻ [15] 
Finally, the equation can be now rearranged to determine the absolute concentration of 
the metabolite while additionally accounting for tissue-dependent signal weightings of both the 
metabolite of interest and the water reference: 
 �ெ = ௌಾ(�ಸಾ�ಹమೀ,ಸಾோಹమೀ,ಸಾ+��ಾ�ಹమೀ,�ಾோಹమೀ,�ಾ+���ಷ�ಹమೀ,��ಷோಹమೀ,��ಷ)ௌಹమೀோಾሺ�ಸಾ�ಾெ�ಾ+��ಾெ�ಾሻሺଵ−���ಷሻ ቀ#ுಹమೀ#ுಾ ቁ �ுଶை [16] 
Eq. [16] quantifies the concentration of the metabolite of interest corrected for relative water and 
metabolite signal weightings due to signal relaxation and partial volume effects dependent upon 
given proportions of GM, WM and CSF in a localized spectroscopic voxel, and is represented in 
institutional units (i.u.). 
Methods 
Estimation of GABA in GM and WM 
Basis concentrations of GABA in GM and WM in the occipital lobe were estimated in a 
reference cohort of 95 participants (62 females; 23.98 ± 4.48 years). Participants of this reference 
cohort took part in a multimodal imaging study, which involved several other MRI and 
neurophysiological measurements (not reported here) and a detailed psychometric assessment. 
The study was approved by the research ethics committee of the School of Psychology, Cardiff 
University, and all participants provided written informed consent. This dataset was collected 
and analyzed prior to and separately from the present investigation. GABA was measured in the 
medial occipital lobe using Mescher–Garwood point resolved spectroscopy (MEGA-PRESS) 
(36) on a 3 T GE Signa HDx scanner (GE Healthcare, Waukesha, WI) at the Cardiff University 
Brain Research Imaging Centre (CUBRIC). Standard acquisition parameters were used: TE/TR = 
68/1800 ms, voxel size = 30 × 30 × 30 mm3, 332 averages, ON editing pulse = 1.9 ppm, OFF 
editing pulse = 7.5 ppm. Since the GABA signal detected using this spectral editing technique is 
contaminated by a co-edited macromolecule (MM) signal (37), GABA concentration 
measurements are termed GABA+. Eight water-unsuppressed scans were additionally acquired. 
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Tissue water was used as an internal concentration reference, which was corrected for relative 
signal contributions from GM, WM and CSF according to Eq. [14]. Signal attenuation and CSF 
correction factors were also applied to the GABA signal. Tissue volume fractions were 
calculated within the voxel based on a tissue-segmented high-resolution 1-mm isotropic T1-
weighted fast spoiled gradient-echo (FSPGR) structural image (TE/TI/TR = 3.0/450/7.9 ms). 
Full details of quantification and voxel co-registration and segmentation procedures are 
described below. A linear regression analysis was then employed to test the relationship between 
tGM and GABA+ concentration and to estimate MGM and MWM (11). The uncertainty of the 
gradient of the linear function was estimated by calculating a 95% confidence interval (CI) for 
the slope parameter. 
Sensitivity Analysis 
To evaluate the sensitivity of correcting GABA measurements by applying Eq. [13], we 
assessed the impact of performing the correction on simulated data using various assumptions of 
rM. A dataset of 10,000 randomly generated, normally distributed data points was created such 
that the data were correlated according to a [GABA+] by tGM linear function. The mean and 
standard deviation (SD) of each variable and the slope of the best-fit line were based on the 
empirical data from the reference cohort. The simulated GABA+ measurements were then 
corrected for partial volume effects based on values of rM estimated from basis concentrations 
reported in the literature (Table 1). As this tissue correction method is specifically for MRS 
measurements, we restricted our selection of basis concentrations to in vivo MRS studies in 
humans to avoid inherent measurement differences between MRS-measured GABA 
concentration and GABA concentration quantified though “gold standard” histological or ex 
vivo methods. 
As an alternative assessment of sensitivity, we evaluated how the tissue correction 
method impacts on classifying individuals into a given disease class based on their measured 
concentration of GABA. Two datasets were created, a diseased cohort (D+) and a non-diseased 
cohort (D–). For each, 100 normally distributed GABA measurements with corresponding tGM 
values were generated. D+ represented hypothetical cases where a clinical diagnosis for a disease 
had been given and where the mean GABA concentration was (arbitrarily) lower than the mean 
GABA concentration of D– (~1.40 vs. ~1.70 i.u.). Two separate scenarios were then simulated. 
In the first, mean tGM for each cohort was approximately equal (~0.47). This corresponded to a 
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scenario where a diseased cohort exhibits no concomitant cortical atrophy. In the second 
scenario, D+ had a lower mean tGM than D– (~0.40 vs. ~0.47), thereby simulating disease-related 
cortical atrophy. For the purposes of this analysis, it was assumed that in both cohorts there was 
a linear dependence of GABA on tGM, where rM ≈ 2. This value was chosen as the assumption of 
rM for the tissue correction in both scenarios. To assess the discriminative sensitivity of the 
GABA measure before and after tissue correction, receiver operating characteristic (ROC) curves 
were plotted and corresponding areas under the curve (AUC) calculated. 
Empirical Validation 
In Vivo GABA Detection 
In vivo GABA concentration was quantified in an independent cohort of 32 volunteers 
(17 females; 26.1 ± 3.2 years). This study was approved by the research ethics committee of the 
School of Psychology, Cardiff University, and all participants provided written informed 
consent. 
A 30 × 30 × 30 mm3 voxel was positioned medially in the occipital lobe with the ventral 
face of the voxel aligned with the cerebellar tentorium (Fig. 2a). GABA was detected with two 
15-min MEGA-PRESS acquisitions on a 3 T GE Signa HDx scanner at CUBRIC. A standard 
acquisition (TE = 68 ms) was used where Gaussian editing pulses (16 ms duration) were placed 
at either 1.9 ppm (ON) or 7.5 ppm (OFF), which leads to an MM-contaminated GABA signal 
(GABA+). A second acquisition (TE = 80 ms) using the symmetric MM suppression method 
(38,39) was also employed. Here, the editing pulses (20 ms duration) were placed symmetrically 
about the 1.7 ppm MM resonance (ON = 1.9 ppm, OFF = 1.5 ppm). The MM resonance is in this 
way excited equally in both ON and OFF scans, and the co-edited MM resonance, which is 
present to the same extent in both ON and OFF scans, is absent in the difference spectrum. These 
concentration measurements are termed GABA'. Other scan parameters for both acquisitions 
were as follows: TR = 1800 ms, 512 averages, 4096 data points, 5 kHz spectral width. For 
PRESS localization, the sequence included a 3.6-ms 90° slice-selective sinc excitation pulse (2.4 
kHz bandwidth) and two 5.2-ms 180° slice-selective sinc refocusing pulses (1.2 kHz bandwidth). 
Eight water-unsuppressed scans were acquired in each acquisition from which the water signal 
acted as an internal concentration reference. 
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A high-resolution T1-weighted FSPGR structural image (TE/TI/TR = 3.0/450/7.9 ms, flip 
angle = 20°, voxel resolution = 1 mm3, FOV = 256 × 256 × 168 mm3, matrix size = 256 × 256) 
was acquired for voxel co-registration and tissue segmentation. 
Voxel Co-Registration and Segmentation 
MRS voxels were co-registered with the FSPGR image using in-house software created 
in MATLAB, producing a binary voxel mask in individual structural space. Structural images 
were segmented into probabilistic partial volume maps corresponding to GM, WM and CSF 
using the automated segmentation tool FAST (40) in FSL following removal of non-brain tissue 
using BET (41). Each partial volume map was then multiplied by the binary voxel mask to give 
probabilistic partial volume voxel maps (Fig. 2). The volume of each tissue compartment was 
calculated by multiplying the volume of tissue (in voxels) in each partial volume map by the 
mean partial volume estimate. fGM, fWM and fCSF were then calculated by dividing the voxel 
volume of each tissue compartment by the sum of the voxel volumes. tGM was calculated by 
dividing fGM by the sum of fGM and fWM. 
GABA Quantification 
Spectra were processed and GABA was quantified in Gannet (42) using the software’s 
standard processing steps. Three-hertz exponential line broadening was applied to time-domain 
data prior to Fourier transformation. The data were automatically corrected for frequency and 
phase drift using spectral registration (43) and Fourier-transformed into the frequency domain. 
Using a nonlinear least-squares fitting algorithm, the integral of the GABA signal was calculated 
by fitting a Gaussian function to the GABA peak in the difference spectrum (Fig. 3). The integral 
of the water signal was calculated by fitting a Lorentzian-Gaussian function to the water peak in 
the unsuppressed water spectrum. GABA concentration measurements were then standardized to 
internal tissue water in three separate ways: (i) by only multiplying the signal ratio of GABA to 
water (SM / SH2O) by a global concentration scaling factor (#HH2O / #HGABA × CH2O), (ii) by 
additionally correcting the water signal for tissue-dependent signal relaxation and water density 
differences according to Eq. [14] or (iii) by performing a full tissue correction where both the 
water and GABA signals are corrected for partial volume effects according to Eq. [16]. For the 
quantification of GABA concentration where the GABA signal is detected using spectral editing 
it is necessary to further correct for the estimated degree of MM contamination and for editing 
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efficiency (MM / κ). MM is the estimated amount of GABA in the MM-contaminated GABA 
signal (0.45) and κ is the editing efficiency of GABA-editing (0.5). Note that for the purposes of 
this study and the sake of consistency the MM correction factor was also applied to the MM-
suppressed GABA measurements, meaning that the reported concentration values are 
approximately half of what would normally be expected. The relative water densities in CSF, 
GM and WM were assumed to be 1.00, 0.78 and 0.65 (31). The T1 and T2 of water were 
respectively assumed to be 1.33 s and 0.11 s in GM, 0.83 s and 0.08 s in WM (44) and 3.82 s 
(45) and 0.50 s (46) in CSF. The T1 and T2 of GABA were assumed to be 0.80 s and 0.088 s (19). 
Two protons give rise both to the water peak and the GABA peak. MWM and rM were estimated 
from the reference dataset. Given the uncertainty of the regression slope as assessed by the 95% 
CI, the optimal rM value was chosen from 100 values calculated by linearly interpolating 
between the upper and lower bounds of the CI for MGM (at tGM = 1). MWM (at tGM = 0; i.e., the 
intercept in the regression model) was kept fixed (see Table 1). The optimal rM value was that 
which produced the smallest possible coefficient of determination (R2) when GABA 
concentration was regressed against tGM (following correction of the water signal). 
Results 
Mean ± SD [GABA+] and tGM in the reference cohort was 1.71 ± 0.25 i.u. and 0.47 ± 
0.07, respectively. The two variables were significantly linearly related (R2 = 0.12, p < 0.001) 
(Fig. 4), replicating previous findings of a dependency of GABA concentration on GM tissue 
volume. The slope parameter equaled 1.16, and the 95% CI of this was [0.51, 1.81]. 
Extrapolating from the regression model, the basis concentrations of GABA in pure GM and 
WM (MGM and MWM) were estimated to be 2.32 i.u. and 1.16 i.u, respectively (rM = 2.00). 
The outcome of the simulated sensitivity analysis is displayed in Figure 5. As expected, 
the assumption of rM taken from the reference cohort resulted in the largest reduction in the 
variance shared by [GABA+] and tGM (R2 = 0.001). This was followed by assumptions of rM 
taken from previous empirical studies that estimated a ratio between approximately 1.5 and 3 (R2 
< 0.03). Conversely, assumptions of rM above 6 introduced more shared variance into the 
regression model (R2 > 0.17). This led to overcorrection, demonstrated by the inflation of GABA 
measurements in voxels composed predominantly of WM. Correcting for partial volume effects 
using appropriate assumptions of rM also reduced the amount of variance within the GABA 
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dataset (σ2) compared to the original uncorrected dataset. Overcorrection resulted in increased 
variance within the GABA dataset. 
The ROC curves are plotted in Figure 6. Correcting the GABA measurements when there 
were no tissue differences between D+ and D– led to a small increase in the AUC (0.78 vs. 0.81). 
This is a result of a decrease in variance within the GABA datasets for both cohorts, which 
improved discriminative sensitivity. Conversely, the AUC decreased after correction in the 
scenario where atrophy was simulated in D+ (0.79 vs. 0.76). Since the tissue correction will raise 
concentration values measured in predominately WM voxels to remove the tissue dependence 
(Fig. 1), the overlap in the distributions of the GABA datasets for both cohorts increased, leading 
to decreased discriminative sensitivity. 
Thirty-one pairs of good quality spectra were acquired in the validation experiment. One 
participant’s data were excluded because of a large linewidth as a result of poor B0 shimming. 
Mean ± SD [GABA+] was 1.53 ± 0.10 i.u. and mean ± SD [GABA'] was 0.74 ± 0.11 i.u (water 
tissue-corrected). Tissue segmentation showed an average tGM of 0.41 ± 0.06 across voxels. 
Regression models of the dependence of GABA concentration on tGM for MM-contaminated and 
MM-suppressed measurements are displayed in Figure 7. Correcting the water signal alone 
revealed a linear dependence of [GABA+] on tGM (R2 = 0.12). This dependency was weaker for 
GABA' (R2 = 0.04). [GABA+] was estimated to be 1.89 i.u. in pure GM and 1.29 i.u. in pure 
WM (rM = 1.47). For [GABA'], this was 0.97 i.u. in GM and 0.58 i.u. in WM (rM = 1.67). 
Performing a full tissue correction led to a substantial reduction in the variance shared 
between GABA concentration and tGM for both GABA+ and GABA' measurements when 
compared to only correcting the water signal (R2 < 0.001). The optimal rM taken from the range 
of interpolated ratios was 1.45 for GABA+ and 1.57 for GABA'. Additionally, this full 
correction method did not introduce more variance into the GABA datasets in comparison to the 
water tissue correction. F-tests for equality of variances showed that the variances of the two 
tissue-corrected datasets were not significantly different from each other for either the GABA+ 
(F(30, 30) = 1.05, p = 0.90) or GABA' datasets (F(30, 30) = 0.97, p = 0.93). 
Discussion 
The simulations of the sensitivity of correcting for heterogeneous tissue content 
demonstrate that significant care needs to be taken when assuming the ratio of intrinsic 
metabolite concentration in GM and WM. An inappropriately large ratio will lead to 
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overcorrection and introduction of an unwanted negative correlation with fractional GM volume. 
This would be particularly detrimental for concentrations quantified from data acquired in 
predominately WM voxels as these values will be greatly inflated. When an appropriate 
assumption of rM is used, however, correction for partial volume effects can substantially reduce 
the variance shared between the quantified metabolite and fractional GM volume, and in 
principle can decrease the between-participant variance within the metabolite dataset itself. With 
respect to studies investigating individual or group differences in metabolite levels, appropriately 
performing a full tissue correction has the benefit of improving the ability to discern true 
differences by reducing variance of no interest and increasing the power of statistical tests. This 
conclusion is further supported by the ROC simulations, where the discriminative sensitivity of 
measured GABA concentration to classify individuals into a given disease class is increased 
because of reduced between-participant variance in tissue-corrected datasets. Importantly, 
however, if there are meaningful tissue differences between two cohorts then the tissue 
correction will rectify overestimation of discriminative sensitivity. 
A valid concern is that normalizing GABA measurements as described in this paper may 
potentially be counterproductive and could increase error, especially if incorrect basis 
concentrations are assumed. However, tests for equality of variances demonstrated that this 
additional correction did not add more variance to the GABA datasets. Therefore, we show that 
correcting GABA concentration for heterogeneous tissue content is a straightforward and viable 
step in quantification methodology in MRS. This method can be easily applied to other 
metabolites that are known to exhibit a dependence on GM volume. 
Our findings largely mirror the results from Harris et al. (19). The ratio of intrinsic 
GABA in GM and WM in the occipital lobe was found to be approximately 2 in our reference 
dataset, which is equal to the ratio the authors recommend for partial volume tissue correction for 
GABA measurements (rM is the inverse of what they call α in Eq. (β) in their paper). Our study 
differs in several key ways, however. Firstly, by having access to a reference dataset with an 
uncharacteristically large sample size, we were able not only to robustly estimate rM in a specific 
region but to also gauge the degree of uncertainty of the slope parameter of the regression model 
assessing GM tissue volume as a predictor of GABA concentration. We then were able to apply 
this empirically informed estimation of rM to correct an independent dataset using a similar MRS 
acquisition protocol, demonstrating validation of the tissue correction method. Secondly, in our 
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simulations assessing the sensitivity of the tissue correction, we purposely selected estimations 
of rM from previous studies in the literature to highlight explicitly that there are several available 
empirical sources that can inform on an appropriate (or inappropriate) assumption of rM. Finally, 
we acquired MM-suppressed GABA measurements using symmetric MM suppression in 
addition to GABA+ measurements, and show that the tissue correction method can also be 
applied to this more specific measure of GABA. These methodological differences from Harris 
et al.’s investigation corroborate their approach, further validating the use of an assumed ratio of 
intrinsic GM and WM GABA as a method for accounting for partial volume effects. 
To account for the possibility that group or individual differences are attributed to 
differences in GM volume, it is sometimes usual to treat tGM as a covariate of no interest (e.g., by 
analysis of covariance or linear regression). Intuitively, this appears to be a sensible approach, 
given that the aim of an experiment should be to demonstrate that the variance of a dependent 
variable (e.g., GABA concentration) is mostly explained by the independent variable (e.g., 
younger vs. older participants) alone, independent of the variance explained by a covariate, such 
as tGM. However, it is a common mistake to attempt to control for a covariate when the covariate 
(in this case, tGM) is related to both the dependent and independent variables. Covarying out a 
covariate that correlates with both of these variables will not just remove some of the 
unexplained variance, it will also remove variance that would have been attributable to the 
predicted effect (47). This makes interpreting the outcome of the study problematic and reduces 
the ability to observe true effects that may otherwise have been evident prior to partialling out 
the variance attributed to the covariate. The alternative method of normalizing GABA 
concentration for partial volume effects as presented here obviates this issue as any variance of a 
covariate shared between GABA concentration and another variable of interest is removed from 
the GABA measure only. Notably, this approach can be implemented regardless of whether GM 
volume is associated with GABA and another variable of interest or with GABA alone. 
The estimations of the basis concentrations of GABA in GM and WM from previous 
MRS studies reveal a considerable range in ratios (~1.5–8). This discrepancy is problematic as it 
adds uncertainty to the appropriate assumption of rM. It is unclear why such a range of 
estimations exists, but one possible explanation is that this is down to the variety of spectroscopy 
techniques that have been employed. The majority have employed SVS, where the exact 
acquisition approach has included double quantum filtering (15), ultra high-field unedited 
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spectroscopy (18) and J-difference editing (16,17,48). Approaches in CSI experiments have also 
varied from multiple quantum filtering (14) to 2D J-resolved (12) or J-difference edited imaging 
(13). All of these methods have their own advantages and disadvantages with regard to resolving 
the GABA signal (49), which may play a factor in the inconsistent estimations of MGM and MWM. 
There is also the problem of different tissue segmentation algorithms and how much they 
contribute to quantification error. There is already some indication that some of the major 
toolboxes result in more error than others (35,50). The choice of concentration reference in 
previous studies is also an important point to consider when explaining the inconsistency of these 
estimates. Tissue water and creatine are the most commonly used internal references and both 
require assumptions about their respective intrinsic concentration in the sample prior to 
conversion to absolute concentration values, adding uncertainty to estimates of basis 
concentrations. Another plausible explanation is that the sample size in most of these previous 
investigations has been relatively small (typically three to 10 participants). Even for CSI, where 
the number of voxels allows for a better estimation of basis concentration across tissue type (at 
least across brain regions), a small sample size limits the generalisability of estimated basis 
concentrations. Finally, MM contamination in MEGA-edited spectroscopy will add some 
variance to the relationship between GABA measurements and GM volume. At least one CSI 
study has reported a relationship between GM and the MM baseline (51). Indeed, in our 
independent validation dataset rM was estimated to be lower for the MM-suppressed 
measurements compared to the MM-contaminated measurements. Given these discrepancies, we 
recommend that research groups use reported values of MGM and MWM taken from previous 
studies that implemented a similar acquisition technique, set of sequence parameters, 
concentration reference and/or region of interest. Ideally, a reference dataset acquired from a 
sufficiently large sample at the local research site should be used, but this will not always be 
possible in some settings. 
Aside from the inconsistency in rM for GABA in the literature, a major limitation with the 
approach described here is the assumption that this ratio is constant throughout the cerebrum. 
Given the variation in GABA levels in different cortical and subcortical regions (2,7,10), it is 
plausible that there are regional differences in the basis concentrations of GABA in GM and 
WM. Additionally, the correction also assumes that rM is the same for all individuals, which is 
unlikely to be the case. To overcome these limitations, rM would need to be estimated within the 
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region of interest on a per-participant basis, such as by using CSI. Methodological limitations 
and time constraints make this impractical, however, particularly in a clinical setting. 
Alternatively, and as previously stated, a sufficiently large reference dataset that matches the 
technique and region of interest would circumvent these issues to a certain extent. 
Although accounting for differences in the basis concentration of GABA in GM and WM 
will reduce tissue-dependent signal heterogeneity across participants within a given study, other 
factors influencing absolute quantification will affect measurements both within and across 
datasets. For instance, chemical shift displacement artifacts will have an impact on tissue 
correction procedures given the effective spatial offset of the detected metabolite signal of 
interest from the nominal voxel from which tissue values are derived. Such signal localization 
errors will be particularly problematic with PRESS as the slice-selective refocusing pulses 
typically have relatively low bandwidths and, therefore, suboptimal spatial profiles. To reduce 
error contributed from these artifacts to tissue correction, the chemical shift displacement of the 
GABA signal could be determined and tissue values derived from the effective voxel. Relatedly, 
spatial effects of the MEGA-PRESS experiment will lead to signal loss in particular 
compartments of localized volumes (52,53), which can only be assessed through numerical 
simulations or in vitro experiments. In addition, the lineshape of the resolved difference-edited 
3.0 ppm GABA multiplet will differ depending on the transition width, refocusing bandwidths 
and flip angles of the slice-selective refocusing pulses (54). These will differ across acquisition 
protocol, platform and research site, leading to subtle differences in quantified measures. Finally, 
it is assumed that the relaxation times of the metabolite of interest are equal or at least similar 
between GM and WM. Although the in vivo T1 and T2 of GABA have been measured previously 
(19), relaxation differences across tissue type have yet to be characterized and should eventually 
be taken into account in the absolute quantification procedure. These issues highlight some of the 
continued difficulties of absolute quantification in MRS, and in particular the absolute 
quantification of GABA. 
A method to correct GABA concentration measurements for partial volume effects in 
MRS volumes with heterogeneous tissue compositions has been presented and validated. This 
approach is an extension of an established method that quantifies metabolite concentration using 
tissue water as an internal reference while correcting for differential water signal contributions 
across tissue type. Although care must be taken when assuming the basis concentration of 
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GABA in GM and WM, appropriate assumptions will remove the tissue dependence and could 
potentially reduce measurement-related variance within the dataset of GABA measurements, 
enhancing the power of MRS studies of individual differences and pathological changes in 
neuropsychiatric and neurological disorders.  
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Figure 1. The modelled multiplicative tissue correction factor (Tcorr) for assumed rM values 
ranging from 1 to 10 as a function of fractional GM volume per unit tissue volume (tGM). 
Assumption of a large rM necessitates a greater correction for voxels composed predominately of 
WM, leading to inflation of concentration measurements. The model assumes that the 
concentration of the metabolite in CSF is negligible, that fCSF = 0 and that there are no metabolite 
relaxation differences between GM and WM. 
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Figure 2. High-resolution T1-weighted structural image for one participant with the co-registered 
MRS voxel mask displayed in yellow (a). Corresponding probabilistic partial volume voxel maps 
following FAST tissue segmentation are shown for GM (b), WM (c) and CSF (d). 
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Figure 3. Sample difference spectra from the same participant using standard GABA editing 
(GABA+) (a) and symmetric MM suppression (GABA') (b). The MM-suppressed spectrum 
shows a clear reduction in the 3.0 ppm GABA peak amplitude, indicating removal of the co-
edited MM signal. Model fits of the Gaussian function to the GABA peak in each spectrum are 
shown in red. The residuals below each of the fits demonstrate good performance of the fitting 
procedure. 
 
 
Figure 4. Linear dependence of [GABA+] on tGM in the reference dataset (n = 95). The solid 
black line is the line of best fit in the linear regression model. The dashed red lines represent the 
95% CI for the upper and lower bound of the slope parameter. 
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Figure 5. Simulated sensitivity analysis of normalizing the linear dependence of [GABA+] on 
tGM by assuming various assumptions of rM (shown in parentheses) estimated from the reference 
dataset and previous empirical studies. The scatterplot with blue data points shows the 
uncorrected data while the scatterplots with red data points show corrected data based on each 
assumption of rM. The black lines are the lines of best fit in each linear regression model. The 
coefficient of determination of each model (R2) and the variance within each simulated GABA 
dataset (σ2) are also displayed. 
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Figure 6. Receiver operating characteristic (ROC) curves illustrating the impact of correcting 
GABA measurements for tissue-dependent concentration differences in hypothetical diseased 
(D+) and non-diseased (D–) cohorts. Two scenarios were simulated: one where atrophy was not 
present in D+ and one where atrophy was present in D+. The uncorrected ROC curves (blue) in 
both scenarios had an area under the curve (AUC) of ~0.80. When both cohorts exhibited similar 
mean tGM values (no atrophy scenario), the tissue correction led to a small increase in the AUC 
(red ROC curve). When D+ had a lower mean tGM (atrophy scenario), the tissue correction led to 
a decrease in the AUC. 
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Figure 7. Scatterplots of tGM versus [GABA+] (top row) and versus [GABA'] (bottom row) (n = 
31). The leftmost column displays the relationship between tGM and GABA measurements 
following application of a global concentration scaling factor only. The middle column displays 
the same relationship following additional tissue correction of the water signal only. The 
rightmost column shows the relationship when water and GABA are both tissue-corrected. R2 = 
coefficient of determination; p = p-value; σ2 = variance within the GABA dataset. 
